Bacterial (Pyogenic) Meningitis - Pipeline Insight 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
’Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2018 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Bacterial (Pyogenic) Meningitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Bacterial (Pyogenic) Meningitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Bacterial (Pyogenic) Meningitis pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Bacterial (Pyogenic) Meningitis Overview
3. Pipeline Therapeutic
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
Companies MentionedAstraZeneca Sanofi Pasteur GlaxoSmithKline Beijing Zhifei Lvzhu Biopharmaceutical Co. Ltd Aberabio Novartis
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/brn7fw/bacterial?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005376/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs,Infectious Diseases Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/21/2018 11:33 AM/DISC: 12/21/2018 11:32 AM